236 related articles for article (PubMed ID: 34434611)
1. PD-1 inhibition in patient derived tissue cultures of human gastric and gastroesophageal adenocarcinoma.
Hußtegge M; Hoang NA; Rebstock J; Monecke A; Gockel I; Weimann A; Schumacher G; Bechmann I; Lordick F; Kallendrusch S; Körfer J
Oncoimmunology; 2021; 10(1):1960729. PubMed ID: 34434611
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in Gastric Cancer.
Högner A; Moehler M
Curr Oncol; 2022 Mar; 29(3):1559-1574. PubMed ID: 35323331
[TBL] [Abstract][Full Text] [Related]
3. The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction.
Valkema MJ; Mostert B; Lagarde SM; Wijnhoven BPL; van Lanschot JJB
Updates Surg; 2023 Feb; 75(2):313-323. PubMed ID: 35836094
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in esophagogastric cancer.
Ilson DH
Clin Adv Hematol Oncol; 2021 Oct; 19(10):639-647. PubMed ID: 34637430
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Joshi SS; Maron SB; Catenacci DV
Future Oncol; 2018 Feb; 14(5):417-430. PubMed ID: 29094609
[TBL] [Abstract][Full Text] [Related]
6. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
7. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.
Saito R; Sawada Y; Nakamura M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410
[TBL] [Abstract][Full Text] [Related]
8. Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment.
Jomrich G; Kollmann D; Ramazanova D; Ristl R; Grose RP; Ilhan-Mutlu A; Preusser M; Fassnacht C; Tsai YC; Guenova E; Schoppmann SF
Eur J Surg Oncol; 2022 Feb; 48(2):383-390. PubMed ID: 34404561
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort.
Schlintl V; Huemer F; Rinnerthaler G; Melchardt T; Winder T; Reimann P; Riedl J; Amann A; Eisterer W; Romeder F; Piringer G; Ilhan-Mutlu A; Wöll E; Greil R; Weiss L
BMC Cancer; 2022 Jan; 22(1):51. PubMed ID: 35012477
[TBL] [Abstract][Full Text] [Related]
10. PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research.
Zhang Y; Mou GZ; Li TZ; Xu WT; Zhang T; Xue H; Zuo WB; Li YN; Luo YH; Jin CH
Technol Cancer Res Treat; 2021; 20():15330338211004942. PubMed ID: 33759637
[TBL] [Abstract][Full Text] [Related]
11. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
Weinberg BA; Xiu J; Hwang JJ; Shields AF; Salem ME; Marshall JL
Oncologist; 2018 Oct; 23(10):1171-1177. PubMed ID: 29703766
[TBL] [Abstract][Full Text] [Related]
12. PD-1 and PD-L1 inhibitors in oesophago-gastric cancers.
Akin Telli T; Bregni G; Camera S; Deleporte A; Hendlisz A; Sclafani F
Cancer Lett; 2020 Jan; 469():142-150. PubMed ID: 31669518
[TBL] [Abstract][Full Text] [Related]
13. Case Report: Sustained Remission Due to PD-1-Inhibition in a Metastatic Melanoma Patient With Depleted B Cells.
Wulfken LM; Becker JC; Hayajneh R; Wagner AD; Schaper-Gerhardt K; Flatt N; Grimmelmann I; Gutzmer R
Front Immunol; 2021; 12():733961. PubMed ID: 34675925
[TBL] [Abstract][Full Text] [Related]
14. Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade.
Natoli M; Bonito N; Robinson JD; Ghaem-Maghami S; Mao Y
Cancer Immunol Immunother; 2020 Aug; 69(8):1391-1401. PubMed ID: 32200422
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab in gastric/gastroesophageal junction cancer: real-world data from UK Early Access to Medicines Scheme.
Soni M; Kiff C; Carroll R; Stein D; Saragoussi D; Nassar A; Maisey N; Tyas D
Future Oncol; 2021 Aug; 17(24):3163-3174. PubMed ID: 34098737
[TBL] [Abstract][Full Text] [Related]
16. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy.
Shi J; Liu J; Tu X; Li B; Tong Z; Wang T; Zheng Y; Shi H; Zeng X; Chen W; Yin W; Fang W
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101942
[TBL] [Abstract][Full Text] [Related]
17. Peripheral CD4
Xia L; Wang H; Sun M; Yang Y; Yao C; He S; Duan H; Xia W; Sun R; Yao Y; Chen Z; Zhao Q; Li H; Lu S; Wang Y
Sci China Life Sci; 2021 Oct; 64(10):1590-1601. PubMed ID: 33521853
[TBL] [Abstract][Full Text] [Related]
18. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
Front Immunol; 2020; 11():620166. PubMed ID: 33584714
[TBL] [Abstract][Full Text] [Related]
19. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.
Thomas J; Leal A; Overman MJ
Clin Colorectal Cancer; 2020 Jun; 19(2):73-81. PubMed ID: 32173280
[TBL] [Abstract][Full Text] [Related]
20. A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors.
Tobias J; Battin C; De Sousa Linhares A; Lebens M; Baier K; Ambroz K; Drinić M; Högler S; Inic-Kanada A; Garner-Spitzer E; Preusser M; Kenner L; Kundi M; Zielinski CC; Steinberger P; Wiedermann U
Front Immunol; 2020; 11():895. PubMed ID: 32528470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
